# Data Sheet (Cat.No.T35816)

TargetMol

ZLY032

## Chemical Properties



CAS No. : 2314465-67-1

Formula: C22H18F3NO4S

Molecular Weight: 449.44

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

## Biological Description

| | |
|---|---|
| Description | ZLY032 is a dual agonist of free fatty acid receptor 1 (FFAR1/GPR40; EC50= 68 nM in a FLIPR assay) and peroxisome proliferator-activated receptor δ (PPARδ; EC50= 102 nM in a reporter assay).1It is selective for FFAR1 and PPARδ over PPARα and PPARγ (EC50s = >10 μM for both). ZLY032 (40 mg/kg, twice per day) reduces blood glucose levels in an oral glucose tolerance test and decreases plasma total cholesterol and triglyceride levels in theob/obmouse model of metabolic disease.2It reduces hepatic steatosis and plasma alanine transaminase (ALT) and aspartate aminotransferase (AST) levels in a mouse model of non-alcoholic steatohepatitis (NASH) induced by a methionine and choline-deficient diet at the same dose. |
| Targets(IC50) | Others,PPAR |

## Solubility Information

| | |
|---|---|
| Solubility | DMSO:PBS (pH 7.2) (1:5): 0.16 mg/mL (0.36 mM),Sonication is recommended.<br>DMSO: 30 mg/mL (66.75 mM),Sonication is recommended.<br>DMF: 30 mg/mL (66.75 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 2.225 mL | 11.125 mL | 22.2499 mL |
| 5 mM | 0.445 mL | 2.225 mL | 4.450 mL |
| 10 mM | 0.2225 mL | 1.1125 mL | 2.225 mL |
| 50 mM | 0.0445 mL | 0.2225 mL | 0.445 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Li, Z., Chen, Y., Zhou, Z., et al.Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agentsEur. J. Med. Chem.164352-365(2019)

Li, Z., Zhou, Z., Hu, L., et al.ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosisPharmacol Res.159105035(2020)